Navigation Links
Targeting PARP1 Is Effective In Protecting HD Cells from Damage

According to a study conducted by the researchers at the MassGeneral Institute for Neurodegenerative Disease (MIND) it was found that inhibitor of an enzyme known as Poly //(ADP-ribose) polymerase (PARP1) is very effective in protecting Huntington’s disease affected cells from undergoing damage.

By targeting this enzyme new drugs can be developed to treat Huntington's disease (HD) and other disorders characterized by low cellular energy levels. The study results are published in the journal of Chemistry & Biology. ‘While PARP1 is essential for the repair of damaged DNA, we also know that, if overactivated, it can cause cell death by excessive energy depletion,’ says Aleksey Kazantsev, PhD, director of the MIND High Throughput Drug Screening Laboratory, who led the current study. ‘It has recently been shown that neurons from patients with Huntington's appear to be energy-deficient, so we hypothesized that modest stresses that would be tolerated by healthy cells could send HD cells below a viable energy threshold and that blocking PARP1 activation could be protective.’

To test this hypothesis the MIND researchers first ran a computer search of their small-molecule library for potential novel inhibitors of PARP1, searching for those with structural similarities to known inhibitors. ‘Safety and efficacy of human drugs depends on many factors, so it's hard to predict which inhibitor would be most effective against a specific disorder. The more diverse novel inhibitors can be identified, the more chances there are of developing safe and effective drugs,’ Kazantsev explains.

Two candidate molecules were identified as potential PARP1 inhibitors based on their structure, and both of them were confirmed to inhibit the enzyme's activity in an in vitro assay. However, when tested using cultured human and rat cells, only one of the candidate molecules, K245-14, successfully prevented the death of cells in which PARP1 had been overactivated. The nex t assays examined whether blocking PARP1 activity with K245-14 could reduce energy depletion in cells with the HD genetic mutation. Using cells from human HD patients and from a mouse model of the disorder, the MIND researchers compared the reactions of HD cells to oxidative stress caused by the application of hydrogen peroxide with the reactions of normal cells.

Although all of the cells reacted with a loss of ATP, a key source of cellular energy, the HD cells – which had much lower ATP levels to begin with – were much more vulnerable to stress-induced energy loss. Inhibiting PARP1 by means of K245-14 reduced ATP loss in all tested cells and significantly protected against both energy loss and cell death in the HD cells. ‘While we were pleased to observe these predicted protective effects in our experiments, validation of PARP1 as a useful HD drug target will require the testing of inhibitors in animal trials,’ Kazantsev explains.

The process of identifying the best candidates for trials will be very complex, since any drug treating a central nervous system disorder needs to penetrate the blood-brain barrier. We will be working with our collaborators at the Scripps Research Institute – world leaders in computational chemistry – to conduct a more comprehensive virtual screen and select additional promising candidates for drug development. ‘Inhibition of PARP1 activity is thought to be potentially beneficial for treatment of cancer, neurodegenerative conditions such as Parkinson's disease, and over twenty other human disorders,’ he adds. ‘We envision broad therapeutic applications for small molecule inhibitors of PARP1.’ Kazantsev is an assistant professor of Neurology at Harvard Medical School.

Souce: Eurekalert
'"/>




Related medicine news :

1. Novel Technique For Targeting Small-Cell Lung Cancer
2. Ad Campaign Targeting Republicans On Medicare Prescription Drug Program
3. By Targeting Specific Germs, Hospital Hopes to Improve Pneumonia Treatment
4. Highly Potent TB Strain Plays Favorites Targeting Specific Ethnic Groups
5. New Asthma Medicine Targeting Vulnerable Inner-City Children Tested
6. Targeting a Single Gene Could Inhibit Bone Decay and Stimulate Bone Growth
7. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
8. Targeting the Adrenal Gland Could Be Key Against Heart Failure
9. Targeting SOCS-3 can Control Obesity
10. Sex Abstinence Programs Targeting School-goers may Not Produce Desired Effect , Study
11. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of ... not surprising that bariatric surgery has received increased attention in recent years, as an ... when it comes to weight loss, most people are familiar with the basic requirements ...
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
(Date:5/27/2016)... ... 2016 , ... Beleza Medspa has initiated a new program to ... the first time that Coolsculpting is being used for for more than just cosmetic ... they meet the prescribed body-fat standard, measured by the circumference-based tape method. The ...
(Date:5/27/2016)... Wis. (PRWEB) , ... May 27, 2016 , ... ... $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... accepted her award on May 18 at the university’s Student Leadership Awards ceremony. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... 2016 According to a new ... 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by ... Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", published ... Market for the forecast period of 2016 to 2021. ... by 2021 from USD 117.3 Million in 2016, at ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
Breaking Medicine Technology: